CN111264879A - Synbiotic and application thereof - Google Patents
Synbiotic and application thereof Download PDFInfo
- Publication number
- CN111264879A CN111264879A CN202010071355.5A CN202010071355A CN111264879A CN 111264879 A CN111264879 A CN 111264879A CN 202010071355 A CN202010071355 A CN 202010071355A CN 111264879 A CN111264879 A CN 111264879A
- Authority
- CN
- China
- Prior art keywords
- powder
- oligosaccharide
- synbiotics
- probiotic
- probiotic powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019722 synbiotics Nutrition 0.000 title claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 54
- 239000006041 probiotic Substances 0.000 claims abstract description 51
- 235000018291 probiotics Nutrition 0.000 claims abstract description 51
- 230000000529 probiotic effect Effects 0.000 claims abstract description 29
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 20
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 19
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 15
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 15
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 14
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 14
- 241001506047 Tremella Species 0.000 claims abstract description 13
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 12
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 12
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 11
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 11
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 claims abstract description 11
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 11
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 claims abstract description 8
- 235000009195 Lactobacillus acidophilus NCFM Nutrition 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims description 20
- 235000013399 edible fruits Nutrition 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- 235000002479 food anti-caking agent Nutrition 0.000 claims description 8
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 8
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 8
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 8
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 20
- 230000036039 immunity Effects 0.000 abstract description 13
- 241000282414 Homo sapiens Species 0.000 abstract description 11
- 230000007413 intestinal health Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 2
- 241000186000 Bifidobacterium Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000009286 beneficial effect Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 241000220223 Fragaria Species 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000305071 Enterobacterales Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 229930182827 D-tryptophan Natural products 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Abstract
The invention discloses a synbiotics and application thereof, wherein the synbiotics comprise prebiotics and probiotic powder, and the prebiotics comprise oligosaccharide, stachyose, tremella polysaccharide and hericium erinaceus instant powder; the probiotic powder comprises lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37 and lactobacillus rhamnosus HN 001. The synbiotics in the scheme of the invention can supplement intestinal probiotics and prebiotics and improve the health of gastrointestinal tracts; meanwhile, the immunity of the human body can be improved, the safety of each component is high, and the prebiotics and the probiotics are added simultaneously, so that the intestinal health can be maintained, and the immunity can be improved.
Description
Technical Field
The invention relates to the technical field of food, in particular to synbiotics and application thereof.
Background
Synbiotics refers to the combined use of probiotics and prebiotics (mainly various dietary fibers). Probiotics (probiotics) are bacteria groups which have beneficial effects on human bodies and can improve the micro-ecology of human bodies, and common intestinal probiotics comprise bifidobacteria, lactobacilli and the like. The probiotics can (1) adjust intestinal flora and inhibit the growth of pathogenic bacteria; (2) regulating immune response, and treating food allergy and inflammatory bowel disease; (3) protect the intestinal barrier function of postoperative patients, reduce the occurrence of infection, and improve prognosis; (4) the prevention and treatment effect in the occurrence and development of tumors; (5) reducing serum cholesterol, and improving digestion. Prebiotics (prebiotics) refer to food ingredients that can act as fermentation substrates to promote the growth of probiotics and exert their beneficial effects, primarily various soluble and insoluble dietary fibers. The prebiotics have the main functions of (1) promoting the growth of probiotics, inhibiting the growth of harmful bacteria and improving the structure of intestinal flora; (2) the metabolite after prebiotics fermentation regulates lipid metabolism, reduces serum triglyceride and the like; (3) regulating the digestive absorption of carbohydrates to smooth postprandial blood glucose levels; (4) relieving constipation. The combined use of probiotics and prebiotics can promote the functions of the two, in short, the prebiotics are fermentation culture media and provide enrichment and growth of probiotics, and the growth metabolites of the probiotics provide nutrition and energy sources for intestinal tracts and produce various B vitamins and short-chain fatty acids to promote the healthy development of the barrier function of the intestinal tracts.
With the rapid development of economy in the 21 st century, the living standard and the scientific and technical standard of people are continuously improved, and the intestinal health is more and more valued by people. Due to the fast-paced life style and irregular eating habits, more and more people suffering from intestinal diseases are in the same age, and the traditional medicine for treating the intestinal diseases has obvious effect but cannot help the intestinal tract to recover the corresponding functions. People with intestinal diseases are often accompanied by hypoimmunity symptoms. The probiotic product treats intestinal tract diseases by supplementing intestinal probiotics, and has obvious effect and high safety. However, the products on the market only aim at supplementing probiotics, and the contribution to the improvement of immunity is not outstanding, so that the development of a product which can remarkably maintain the intestinal health and can improve the immunity is urgent.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art. Therefore, the synbiotics provided by the invention can improve the intestinal flora and improve the good effect of improving the immunity.
The invention also provides application of the synbiotics.
The synbiotics comprise prebiotics and probiotic powder, wherein the prebiotics comprise oligosaccharide, stachyose, tremella polysaccharide and hericium erinaceus instant powder;
the probiotic powder comprises lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37 and lactobacillus rhamnosus HN 001.
The synbiotics provided by the embodiment of the invention at least have the following beneficial effects: fungus polysaccharides (tremella polysaccharides and hericium erinaceus polysaccharides) are added into the prebiotics, and the tremella polysaccharides have good film forming property, can promote the growth of beneficial microorganisms in gastrointestinal tracts, regulate the formation of ideal microbial flora in intestinal tracts, and enhance the resistance of animals to exogenous pathogenic bacteria; can also improve the humoral immunity ability and enhance the phagocytic ability of phagocyte; improving activity and function of lymphocyte, promoting growth of cytokine, protecting erythrocyte membrane from oxidation injury, improving immunity, and enhancing disease resistance. The hericium erinaceus instant powder contains amino acids, proteins and hericium erinaceus polysaccharide, can be combined with receptors on cell membranes, has a good effect on inhibiting helicobacter pylori, has obvious effects of preventing and improving acute and chronic diseases, drug induced diseases and stress gastric mucosa injury models, promotes the formation of immune globulin, increases leukocytes, and improves the lymphocyte conversion rate and the disease resistance of an organism by increasing the phagocytosis of macrophages. In addition, stachyose has obvious proliferation effect on beneficial bacteria such as bifidobacterium, lactobacillus and the like in gastrointestinal tract of human body, and can quickly improve the environment in the digestive tract of human body and regulate microecological balance. The strains in the scheme of the invention, namely lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37 and lactobacillus rhamnosus HN001, are safe and reliable, have long use history, and above all have obvious probiotic effect, can improve intestinal flora and can better synergistically enhance immunity. The prebiotics and the probiotics in the scheme of the invention can better improve the intestinal flora structure of an organism in a synergistic manner, and can also better improve the immunity of the organism.
According to some embodiments of the invention, the synbiotics comprise (by weight parts) oligosaccharides (30-110), stachyose (1-35), tremella polysaccharides (0.1-10), hericium erinaceus instant powder (0.1-5) and probiotic powder (0.1-10); preferably, the synbiotics comprise, by weight, 50-90 parts of oligosaccharides, 5-25 parts of stachyose, 4-10 parts of tremella polysaccharides, 0.5-3 parts of hericium erinaceus instant powder and 4-6 parts of probiotic powder; more preferably, the synbiotics comprise, by weight, oligosaccharides (55-83), stachyose (5-20), tremella polysaccharides (4-10), hericium erinaceus instant powder (0.7-2) and probiotic powder (4-5).
According to some embodiments of the invention, the oligosaccharide comprises fructo-oligosaccharide and galacto-oligosaccharide; preferably, the mass ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is (1-5) to (2-6); more preferably, the mass ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is (2-3) to (3-6). Different types of oligosaccharides are added, so that the proliferation of probiotics can be better promoted.
According to some embodiments of the invention, the lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37, lactobacillus rhamnosus HN001 are in a weight ratio of (2-15): (0.8-1.5): (1.5-8.5): (0.8-2.5); preferably, the number of living bacteria in the synbiotics is 1010CFU/g is higher than the standard. The added probiotics have strong functions in the aspect of enhancing the immunity of the organism while maintaining the quantity of beneficial bacteria in the intestinal tract.
According to a second aspect of the invention, the use of synbiotics as described above in healthcare; preferably, the healthcare is for improving gastrointestinal tract function.
The application of the embodiment of the invention has at least the following beneficial effects: the synbiotics of the scheme of the invention has good industrial application prospect in medical care, and especially has outstanding effect on improving the gastrointestinal tract function.
A beverage comprises the synbiotic.
The beverage according to the embodiment of the invention has at least the following beneficial effects: the beverage provided by the scheme of the invention can supplement intestinal probiotics and prebiotics and improve the health of the gastrointestinal tract; meanwhile, the immunity of the human body can be improved, the safety of each component is high, and the prebiotics and the probiotics are added simultaneously, so that the intestinal health can be maintained, and the immunity can be improved.
According to some embodiments of the invention, the beverage further comprises food adjuncts and/or additives.
According to some embodiments of the invention, the additive comprises a plant fruit powder (such as at least one of strawberry fruit powder, apple fruit powder, banana fruit powder, sweet orange fruit powder, and the like); preferably, the adding proportion of the plant fruit powder and the probiotic powder in the preparation raw materials is (0.1-10): (0.1-10); more preferably, the adding ratio of the plant fruit powder to the probiotic powder is (2-6): (3-6); more preferably, the adding ratio of the plant fruit powder to the probiotic powder is (3-5): (4-5). The beverage is added with additives such as strawberry powder and the like to improve the taste of the beverage.
According to some embodiments of the invention, the food adjunct comprises a food anticaking agent; preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.1-5): (0.1-10); more preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.1-1): (3-5); more preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.3-1): (4-5).
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is a diagram showing the detection result of the intestinal flora structure of mice in the embodiment of the present invention;
FIG. 2 is a bar graph showing the relative proportions of Bifidobacterium and Enterobacteriaceae in the intestine of a mouse in accordance with an embodiment of the present invention;
FIG. 3 is a graph showing the quantitative distribution of Bifidobacterium (A) and Enterobacteriaceae (B) in the intestine of a mouse measured by a real-time fluorescence quantitative method according to an embodiment of the present invention;
FIG. 4 is a graph showing the trend of the numbers of mouse B cells (A) and T cells (B) in the examples of the present invention.
Detailed Description
In order to explain technical contents, achieved objects, and effects of the present invention in detail, the following description is made with reference to the accompanying drawings in combination with the embodiments.
The first embodiment of the invention is as follows: the solid beverage is prepared by the following raw materials in parts by weight according to an equivalent incremental mixing method: 20 parts of fructo-oligosaccharide; galacto-oligosaccharide 35; stachyose 20; probiotic powder 5: 10 of tremella polysaccharide; hericium erinaceus instant powder 3; 6, strawberry fruit powder; calcium silicate 1.
The second embodiment of the invention is as follows: the solid beverage is prepared by the following raw materials in parts by weight according to an equivalent incremental mixing method: 30 parts of fructo-oligosaccharide; galacto-oligosaccharide 53; stachyose 5; 4, probiotic powder: tremella polysaccharide 4; 0.7 of hericium erinaceus instant powder; 3, strawberry fruit powder; 0.3 of calcium silicate.
In the above embodiment, the probiotic powder is composed of lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37 and lactobacillus rhamnosus HN001, and the addition ratio is (4-6): (0.5-1): (1.5-3.0): (0.7-1.2) and the viable count is>1010CFU/g beverage.
The solid beverage prepared in the above embodiment is used for intestinal flora detection experiment:
1. subject: 12 mice were selected, half female and half male.
2. Experimental materials: examples 1 to 2 were conducted to prepare solid beverages.
3. The experimental method comprises the following steps: 12 mice were randomly divided into 3 groups of 4 mice each.
Control group: gavage to administer the same volume of saline;
example 1 group: the synbiotic solid beverage prepared in example 1 was administered with a 10-fold human dose (10g/60 kg. d) by gavage;
example 2 group: the synbiotic solid beverage prepared in example 2 was administered with a 10-fold human dose (10g/60 kg. d) by gavage;
after feeding for 10 days, taking 0.1g of mouse excrement, extracting excrement DNA, and detecting intestinal flora in the mouse excrement by adopting a 16s rRNA high-throughput sequencing technology, wherein the result is shown in figures 1-2; the number of bifidobacteria and enterobacteria in the population was determined by fluorescence quantification and the results are shown in FIG. 3. As can be seen from the figures 1-2, compared with a control group, the synbiotic combined solid beverage can change the intestinal flora structure of mice, improve the relative proportion of beneficial bacteria bifidobacteria in the intestinal tracts of the mice and reduce the relative proportion of conditional pathogenic bacteria enterobacteria. As can be seen from FIG. 3, the results of quantitative detection of Bifidobacterium and Enterobacter in the intestinal tract of mice by fluorescence quantification method and detection of 16s rRNA are good, which indicates that the synbiotics of the present invention can improve and change the intestinal flora structure of mice and increase the amount of Bifidobacterium and Enterobacter. Example 2 also increased the number of bifidobacteria and decreased the enterobacteria ratio, but the effect was slightly inferior to the synbiotics of the examples of the present invention. The probiotics in the composition can increase the number of beneficial bacteria such as bifidobacteria and lactobacilli in intestinal tracts by adding the bifidobacteria and the lactobacilli, and in addition, the prebiotic components in the composition can also be beneficial to the proliferation of the bifidobacteria and the lactobacilli in intestinal tracts, inhibit the growth of conditional pathogenic bacteria, and control the relative proportion of the conditional pathogenic bacteria so that the conditional pathogenic bacteria are below a safety line causing harm to human beings.
And (3) taking the mice fed by the operation to perform an immune cell detection experiment:
after feeding the mice for 10 days, on the same day as the feces, the orbital venous plexus was bled, and the numbers of B cells and T cells were measured by flow cytometry, as shown in FIG. 4, in which the ordinate in FIG. 4 was 10 in order of magnitude6。
As can be seen from fig. 4, the synbiotic combination of the example of the present invention and the solid drink of the example 2 can increase the numbers of B cells and T cells of mice, which is helpful for stimulating the immune response of the mouse body, compared to the control group. In recent years, researches show that the intestinal microorganisms have an indispensable effect on regulating the development of host immunity and maintaining the normal immune function of the organism. The common bifidobacteria and lactobacilli of intestinal microorganisms have thallus components such as teichoic acid (LTA) or biotin, antibacterial substances, polysaccharides and the like secreted to the outside of cells, enter into collective lymph nodes through M cells, activate T cells and B cells, and thus regulate and enhance the immunity of the organism. In experiments, 13 probiotics that showed immune activity were found in Inge Kepert (2016), which exerts immune regulation mechanism through its metabolized D-tryptophan, identified as an immunologically active substance. By feeding D-tryptophan to the mice, the mice are found to have increased lung and intestinal Treg cells, reduced lung Th2 response and relieved respiratory symptoms. Therefore, the synbiotics of the scheme of the invention have the function of improving the immunity of the organism.
The efficacy of the probiotics depends on strains, but not on strains commonly known by people, and the lactobacillus acidophilus NCFM strain in the invention contains 4.43 units of lactase, so that the lactose intolerance generally existing in Asians can be effectively improved; the strain can effectively regulate the immune balance of Th1/Th2, and can balance and regulate the immune system of a human body; research indicates that the strain has the efficacy similar to morphine, increases the pain threshold, reduces the perception of pain and can reduce abdominal pain; the strain has the capability of resisting pathogenic bacteria (such as salmonella, staphylococcus aureus, escherichia coli and the like) brought by common gastrointestinal bacteria and food. Bifidobacterium lactis HN019 is very effective in increasing phagocytic power of neutrophil (PWN) and increasing the killing activity of Natural Killer (NK) cells. Research shows that the cell immune activity of the old can be enhanced by taking the strain every day; the administration of Bifidobacterium lactis HN019 by healthy adults on a daily basis can reduce colonic transit time and improve functional gastrointestinal symptoms. Bifidobacterium lactis HN019 can improve intestinal comfort by reducing occasional pain, abdominal distension and constipation; administration of Bifidobacterium lactis HN019 increased cord blood interferon IFN-. gamma. (IFN-. gamma.has been shown to be associated with a reduction in allergic symptoms). Lactobacillus paracasei Lpc-37 can promote gastrointestinal health. The lactobacillus paracasei Lpc-37 has high tolerance to acid and bile salt under the simulated intestinal environment and can be well adhered to the mucosa on the inner wall of the intestinal tract. In addition, a probiotic formulation comprising this strain was found to reduce antibiotic-induced major intestinal microbial disturbances and to maintain bifidobacteria levels in the intestine. Lactobacillus paracasei Lpc-37 has a positive regulating effect on the immune system. In human clinical research species, lactobacillus paracasei Lpc-37 can promote specific immune response. Lactobacillus rhamnosus HN001 can increase natural immunity. After the ingestion of lactobacillus rhamnosus HN001, the phagocytic capacity of mononuclear and PMN cells and the NK cell activity are significantly increased. Lactobacillus rhamnosus HN001 also can effectively improve atopic dermatitis, and researches show that Lactobacillus rhamnosus HN001 can effectively reduce the risk of high-risk infantile eczema.
The term "oligosaccharide" as used herein means a low-degree polymeric saccharide having 2 to 10 monosaccharide molecules connected by glycosidic bonds to form a straight chain or a branched chain, and the various oligosaccharides used in the examples are commercially available oligosaccharides.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all equivalent changes made by using the contents of the present specification and the drawings, or applied directly or indirectly to the related technical fields, are included in the scope of the present invention.
Claims (10)
1. A synbiotics, including prebiotics and probiotic powder, characterized in that: the prebiotics comprise oligosaccharide, stachyose, tremella polysaccharide and hericium erinaceus instant powder;
the probiotic powder comprises lactobacillus acidophilus NCFM, bifidobacterium lactis HN019, lactobacillus paracasei Lpc-37 and lactobacillus rhamnosus HN 001.
2. The synbiotic according to claim 1, characterized in that: the synbiotics comprise (by weight parts) oligosaccharides (30-110), stachyose (1-35), tremella polysaccharides (0.1-10), hericium erinaceus instant powder (0.1-5) and probiotics powder (0.1-10); preferably, the synbiotics comprise, by weight, 50-90 parts of oligosaccharides, 5-25 parts of stachyose, 4-10 parts of tremella polysaccharides, 0.5-3 parts of hericium erinaceus instant powder and 4-6 parts of probiotic powder; more preferably, the synbiotics comprise, by weight, oligosaccharides (55-83), stachyose (5-20), tremella polysaccharides (4-10), hericium erinaceus instant powder (0.7-2) and probiotic powder (4-5).
3. The synbiotic according to claim 1, characterized in that: the oligosaccharide comprises fructo-oligosaccharide and galacto-oligosaccharide; preferably, the mass ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is (1-5) to (2-6); more preferably, the mass ratio of the fructo-oligosaccharide to the galacto-oligosaccharide is (2-3) to (3-6).
4. The synbiotic according to claim 1, characterized in that: the weight ratio of the lactobacillus acidophilus NCFM to the bifidobacterium lactis HN019 to the lactobacillus paracasei Lpc-37 to the lactobacillus rhamnosus HN001 is (2-15): (0.8-1.5): 1.5-8.5): 0.8-2.5; preferably, the number of living bacteria in the synbiotics is 1010CFU/g is higher than the standard.
5. Use of a synbiotic according to any of claims 1 to 4 in healthcare.
6. Use according to claim 5, for improving gastrointestinal tract function.
7. A beverage characterized by: the beverage comprises the synbiotic according to any one of claims 1 to 4.
8. The beverage according to claim 7, wherein: the beverage also comprises food auxiliary materials and/or additives.
9. The beverage according to claim 6, wherein: the additive comprises plant fruit powder; preferably, the adding proportion of the plant fruit powder and the probiotic powder in the preparation raw materials is (0.1-10): (0.1-10); more preferably, the adding ratio of the plant fruit powder to the probiotic powder is (2-6): (3-6); more preferably, the adding ratio of the plant fruit powder to the probiotic powder is (3-5): (4-5).
10. The beverage according to claim 6, wherein: the food auxiliary materials comprise food anticaking agents; preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.1-5): (0.1-10); more preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.1-1): (3-5); more preferably, the addition ratio of the food anticaking agent to the probiotic powder in the preparation raw materials is (0.3-1): (4-5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010071355.5A CN111264879A (en) | 2020-01-21 | 2020-01-21 | Synbiotic and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010071355.5A CN111264879A (en) | 2020-01-21 | 2020-01-21 | Synbiotic and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111264879A true CN111264879A (en) | 2020-06-12 |
Family
ID=70992323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010071355.5A Pending CN111264879A (en) | 2020-01-21 | 2020-01-21 | Synbiotic and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111264879A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955740A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for relieving and treating atopic dermatitis and application thereof |
| CN112956626A (en) * | 2021-03-09 | 2021-06-15 | 山东泰好生物科技有限公司 | Hericium erinaceus polysaccharide small peptide probiotic solid beverage and production method thereof |
| CN114158705A (en) * | 2021-11-22 | 2022-03-11 | 蕴能(大连)生物科技有限公司 | Freeze-dried fruit block with function of improving intestinal health and preparation method thereof |
| CN114774315A (en) * | 2022-04-13 | 2022-07-22 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus rhamnosus strain LRa05 in preparing immunity enhancing and/or eczema relieving product |
| CN114947035A (en) * | 2022-06-02 | 2022-08-30 | 浙江百山祖生物科技有限公司 | Probiotic solid beverage using edible fungus superfine powder as prebiotics and preparation method thereof |
| CN115105577A (en) * | 2022-07-05 | 2022-09-27 | 长荣生物(广州)有限公司 | Multifunctional probiotic composition and application thereof |
| CN115153030A (en) * | 2022-09-08 | 2022-10-11 | 同芙集团(中国)股份有限公司 | Probiotic composition and application thereof, probiotic product and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN108576822A (en) * | 2018-02-02 | 2018-09-28 | 云南中京国建投资有限公司 | A kind of symphysis unit composition and its preparation and application with strengthen immunity function |
| CN109329419A (en) * | 2018-08-28 | 2019-02-15 | 吉林标普生物科技有限公司 | A kind of functional probiotics solid beverage and preparation method thereof for being able to maintain that intestinal health and improving immunity |
| CN109588724A (en) * | 2019-01-28 | 2019-04-09 | 江西美好时光生物科技有限公司 | A kind of probiotic powder and preparation method thereof improving stomach trouble |
| CN110250389A (en) * | 2019-07-16 | 2019-09-20 | 新绎健康管理有限公司 | A kind of the compound probiotic solid beverage and preparation method of auxiliary adjustment blood pressure and blood lipoid |
-
2020
- 2020-01-21 CN CN202010071355.5A patent/CN111264879A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN108576822A (en) * | 2018-02-02 | 2018-09-28 | 云南中京国建投资有限公司 | A kind of symphysis unit composition and its preparation and application with strengthen immunity function |
| CN109329419A (en) * | 2018-08-28 | 2019-02-15 | 吉林标普生物科技有限公司 | A kind of functional probiotics solid beverage and preparation method thereof for being able to maintain that intestinal health and improving immunity |
| CN109588724A (en) * | 2019-01-28 | 2019-04-09 | 江西美好时光生物科技有限公司 | A kind of probiotic powder and preparation method thereof improving stomach trouble |
| CN110250389A (en) * | 2019-07-16 | 2019-09-20 | 新绎健康管理有限公司 | A kind of the compound probiotic solid beverage and preparation method of auxiliary adjustment blood pressure and blood lipoid |
Non-Patent Citations (1)
| Title |
|---|
| 栾颖等: "《防治心脏病从每天做起 第2版》", 30 April 2014 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955740A (en) * | 2020-08-12 | 2020-11-20 | 量子高科(中国)生物股份有限公司 | Composition for relieving and treating atopic dermatitis and application thereof |
| CN112956626A (en) * | 2021-03-09 | 2021-06-15 | 山东泰好生物科技有限公司 | Hericium erinaceus polysaccharide small peptide probiotic solid beverage and production method thereof |
| CN114158705A (en) * | 2021-11-22 | 2022-03-11 | 蕴能(大连)生物科技有限公司 | Freeze-dried fruit block with function of improving intestinal health and preparation method thereof |
| CN114774315A (en) * | 2022-04-13 | 2022-07-22 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus rhamnosus strain LRa05 in preparing immunity enhancing and/or eczema relieving product |
| CN114774315B (en) * | 2022-04-13 | 2023-12-19 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product |
| CN114947035A (en) * | 2022-06-02 | 2022-08-30 | 浙江百山祖生物科技有限公司 | Probiotic solid beverage using edible fungus superfine powder as prebiotics and preparation method thereof |
| CN115105577A (en) * | 2022-07-05 | 2022-09-27 | 长荣生物(广州)有限公司 | Multifunctional probiotic composition and application thereof |
| CN115153030A (en) * | 2022-09-08 | 2022-10-11 | 同芙集团(中国)股份有限公司 | Probiotic composition and application thereof, probiotic product and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11419885B2 (en) | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk | |
| US10716321B2 (en) | Oligosaccharide mixture and food product comprising same | |
| CN111264879A (en) | Synbiotic and application thereof | |
| Thomas et al. | Probiotics and prebiotics in pediatrics | |
| EP3074020B1 (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children | |
| RU2456008C2 (en) | Sinbiotic for improving intestinal microbiota | |
| US10758555B2 (en) | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section | |
| RU2603285C2 (en) | Bifidobacterium bifidum strains for application in gastrointestinal diseases | |
| RU2448720C2 (en) | Synbiotic mixture | |
| MX2010012905A (en) | Probiotics to improve gut microbiota. | |
| CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
| RU2010101791A (en) | INTESTINAL FLORA MODELING IN HIV PATIENTS | |
| US20050186188A1 (en) | Compositions containing probiotics and polysaccharides and methods of use | |
| CN111567809A (en) | Bifidobacterium animalis BZ11 composite microbial agent with functions of improving immunity and regulating intestinal tract | |
| WO2014178007A2 (en) | A pharmaceutical composition comprising a combination of probiotic and prebiotic | |
| CN114568699B (en) | Composition containing galactooligosaccharides and probiotics and application thereof | |
| CN114568701B (en) | Composition containing fructo-oligosaccharide and probiotics and application thereof | |
| Panggabean et al. | A naturally-stabilized-and-balanced synbiotics as a catalyst to aid in healing anti-microbial-resistance-induced communicable and non-communicable diseases | |
| Solkar et al. | Pre and Probiotics In Paediatrics | |
| WO2022268759A1 (en) | Compositions and methods using a combination of at least one fiber and at least one probiotic to improve microbiome resilience | |
| Combrinck et al. | Probiotics and prebiotics | |
| Weizman | Effect of probiotic infant formulas on protection from infection in child care centers | |
| BALCI | PROBIOTIC NUTRITIONS, HEALTH AND OBESITY | |
| Kinderheilkd | ffiwre# ææd | |
| Bruno | The Lactobacillus species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200612 |
|
| RJ01 | Rejection of invention patent application after publication |